Gansu Longshenrongfa Pharmaceutical Industry Co Ltd
Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD researches, develops, produces, and sells traditional Chinese medicines, medical devices, and health products in China and internationally. It also engages in the cultivation, processing, and sale of chemical drugs and medicinal herbs, as well as pharmaceutical distribution, testing, and inspection services. The company was founded in 2002 and … Read more
Gansu Longshenrongfa Pharmaceutical Industry Co Ltd (300534) - Net Assets
Latest net assets as of September 2025: CN¥756.82 Million CNY
Based on the latest financial reports, Gansu Longshenrongfa Pharmaceutical Industry Co Ltd (300534) has net assets worth CN¥756.82 Million CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.32 Billion) and total liabilities (CN¥567.12 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥756.82 Million |
| % of Total Assets | 57.16% |
| Annual Growth Rate | 23.8% |
| 5-Year Change | -1.52% |
| 10-Year Change | 79.48% |
| Growth Volatility | 75.34 |
Gansu Longshenrongfa Pharmaceutical Industry Co Ltd - Net Assets Trend (2011–2024)
This chart illustrates how Gansu Longshenrongfa Pharmaceutical Industry Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Gansu Longshenrongfa Pharmaceutical Industry Co Ltd (2011–2024)
The table below shows the annual net assets of Gansu Longshenrongfa Pharmaceutical Industry Co Ltd from 2011 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥727.93 Million | +2.31% |
| 2023-12-31 | CN¥711.51 Million | -6.76% |
| 2022-12-31 | CN¥763.13 Million | +4.13% |
| 2021-12-31 | CN¥732.84 Million | -0.85% |
| 2020-12-31 | CN¥739.13 Million | +0.03% |
| 2019-12-31 | CN¥738.88 Million | +2.50% |
| 2018-12-31 | CN¥720.83 Million | +1.21% |
| 2017-12-31 | CN¥712.19 Million | +1.20% |
| 2016-12-31 | CN¥703.74 Million | +73.52% |
| 2015-12-31 | CN¥405.57 Million | +11.70% |
| 2014-12-31 | CN¥363.10 Million | +13.85% |
| 2013-12-31 | CN¥318.92 Million | +86.00% |
| 2012-12-31 | CN¥171.46 Million | +278.11% |
| 2011-12-31 | CN¥45.35 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Gansu Longshenrongfa Pharmaceutical Industry Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2111.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥242.10 Million | 36.56% |
| Common Stock | CN¥303.35 Million | 45.80% |
| Other Components | CN¥116.84 Million | 17.64% |
| Total Equity | CN¥662.28 Million | 100.00% |
Gansu Longshenrongfa Pharmaceutical Industry Co Ltd Competitors by Market Cap
The table below lists competitors of Gansu Longshenrongfa Pharmaceutical Industry Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Jiangxi JDL Environmental Protection Co. Ltd. A
SHG:688057
|
$243.14 Million |
|
BRAZIL RES
F:BSR
|
$243.19 Million |
|
HEBA Fastighets AB (publ)
ST:HEBA-B
|
$243.20 Million |
|
Renxin New Material Co. Ltd. A
SHE:301395
|
$243.27 Million |
|
Favite Inc
TW:3535
|
$243.05 Million |
|
Changzhou Tiansheng New Materials Co Ltd
SHE:300169
|
$242.96 Million |
|
WATERSTONE FINL (MD.)
F:47Z
|
$242.91 Million |
|
Rongyu Group Co Ltd
SHE:002622
|
$242.75 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Gansu Longshenrongfa Pharmaceutical Industry Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 633,705,992 to 662,284,451, a change of 28,578,459 (4.5%).
- Net income of 25,804,597 contributed positively to equity growth.
- Dividend payments of 15,294,105 reduced retained earnings.
- Other factors increased equity by 18,067,967.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥25.80 Million | +3.9% |
| Dividends Paid | CN¥15.29 Million | -2.31% |
| Other Changes | CN¥18.07 Million | +2.73% |
| Total Change | CN¥- | 4.51% |
Book Value vs Market Value Analysis
This analysis compares Gansu Longshenrongfa Pharmaceutical Industry Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.41x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 17.01x to 4.41x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | CN¥0.57 | CN¥9.64 | x |
| 2012-12-31 | CN¥1.34 | CN¥9.64 | x |
| 2013-12-31 | CN¥1.52 | CN¥9.64 | x |
| 2014-12-31 | CN¥1.60 | CN¥9.64 | x |
| 2015-12-31 | CN¥1.78 | CN¥9.64 | x |
| 2016-12-31 | CN¥2.86 | CN¥9.64 | x |
| 2017-12-31 | CN¥2.35 | CN¥9.64 | x |
| 2018-12-31 | CN¥2.38 | CN¥9.64 | x |
| 2019-12-31 | CN¥2.41 | CN¥9.64 | x |
| 2020-12-31 | CN¥2.40 | CN¥9.64 | x |
| 2021-12-31 | CN¥2.37 | CN¥9.64 | x |
| 2022-12-31 | CN¥2.46 | CN¥9.64 | x |
| 2023-12-31 | CN¥2.09 | CN¥9.64 | x |
| 2024-12-31 | CN¥2.18 | CN¥9.64 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Gansu Longshenrongfa Pharmaceutical Industry Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 3.90%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 2.48%
- • Asset Turnover: 0.74x
- • Equity Multiplier: 2.12x
- Recent ROE (3.90%) is below the historical average (8.47%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 30.76% | 10.42% | 1.11x | 2.67x | CN¥9.38 Million |
| 2012 | 14.73% | 11.88% | 0.72x | 1.72x | CN¥8.11 Million |
| 2013 | 12.83% | 14.88% | 0.61x | 1.42x | CN¥9.02 Million |
| 2014 | 16.64% | 20.04% | 0.63x | 1.32x | CN¥24.11 Million |
| 2015 | 14.96% | 21.88% | 0.43x | 1.59x | CN¥20.12 Million |
| 2016 | 6.71% | 17.52% | 0.35x | 1.08x | CN¥-23.12 Million |
| 2017 | 2.40% | 6.35% | 0.34x | 1.10x | CN¥-54.11 Million |
| 2018 | 1.70% | 6.04% | 0.26x | 1.08x | CN¥-59.81 Million |
| 2019 | 1.75% | 5.35% | 0.30x | 1.11x | CN¥-60.28 Million |
| 2020 | 0.25% | 0.72% | 0.29x | 1.19x | CN¥-71.10 Million |
| 2021 | -1.26% | -3.16% | 0.35x | 1.14x | CN¥-81.13 Million |
| 2022 | 3.46% | 6.25% | 0.45x | 1.22x | CN¥-48.78 Million |
| 2023 | 9.73% | 5.71% | 0.81x | 2.11x | CN¥-1.72 Million |
| 2024 | 3.90% | 2.48% | 0.74x | 2.12x | CN¥-40.42 Million |
Industry Comparison
This section compares Gansu Longshenrongfa Pharmaceutical Industry Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $2,123,990,643
- Average return on equity (ROE) among peers: -0.22%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Gansu Longshenrongfa Pharmaceutical Industry Co Ltd (300534) | CN¥756.82 Million | 30.76% | 0.75x | $243.05 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $6.47 Billion | 9.88% | 3.77x | $616.08 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.18 Billion | 2.74% | 0.95x | $320.56 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $10.33 Billion | 15.07% | 0.27x | $3.03 Billion |
| Wedge Industrial Co Ltd (000534) | $298.72 Million | 1.96% | 0.38x | $1.77 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $35.11 Million | 18.13% | 0.80x | $5.62 Billion |
| Hainan Haiyao Co Ltd (000566) | $353.98 Million | -9.58% | 0.80x | $702.18 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $269.51 Million | -61.02% | 1.05x | $317.08 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $927.49 Million | 2.65% | 1.38x | $425.60 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $1.11 Billion | 7.32% | 0.29x | $2.05 Billion |
| Renhe Pharmacy Co Ltd (000650) | $261.49 Million | 10.60% | 0.82x | $777.45 Million |